Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1810631 formulation bridging and food/drug interaction study
NCT05380947Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zongertinib (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 118 hours and Maximum Measured Concentration of BI 1810631 in Plasma at 118 hours. Started Jun 2022; status: completed.
02
Drugs
zongertinib
Beyond the preview
Go deeper on NCT05380947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380947.